[CLSTR]
< Back to situation

[REVISION HISTORY]

Novo Nordisk obesity portfolio: EU approval, legal fight

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-07-25 18:17 UTC → 2026-07-27 01:35 UTC · added removed

Novo Nordisk obesity portfolio expands, portfolio: EU approval, legal fight, access fight

Novo Nordisk’s obesity portfolio continues to grow. In July 2026 the keeps expanding. The European Commission granted confirmed marketing authorisation for the once‑daily oral 25 mg Wegovy tablet across the EU, Norway, Iceland and Liechtenstein, making it oral semaglutide (Wegovy) tablet, the first oral GLP‑1 receptor‑agonist pill approved for weight management in the region. The prescription‑only EU. Based on the OASIS 4 trial, the pill is taken with water before breakfast and achieved produced an average 17 % body‑weight loss in trials. National launch dates are still being set; Novo highlighted the product in a Europe‑wide, product‑neutral Thames‑river exhibition to comply after 64 weeks, with strict advertising rules. one‑third of patients losing about 22 %, and it also demonstrated a 20 % reduction in major cardiovascular events. In the United States States, the oral Wegovy tablet quickly captured strong market share, exceeding three million prescriptions since its January launch and holding about roughly 89 % of the oral GLP‑1 market. Priced at roughly $149 per month, it It is covered under a the Medicare “GLP‑1 Bridge” demonstration that caps patient co‑payments at $50 through 2027; the program, programme, which also includes lets eligible seniors obtain Wegovy, Lilly’s Zepbound and the oral GLP‑1 Foundayo, serves an estimated Foundayo for a fixed $50 monthly copay. The temporary programme expires on 31 December 2027; without a permanent legislative solution, up to 3.8 million seniors but will expire at the end of 2027, raising concerns about future beneficiaries could lose access and higher out‑of‑pocket costs. to treatments that cost over $1,000 a month. Novo Nordisk has intensified escalated its legal battle with Eli Lilly. On 21 July 2026 it filed Lilly, filing a lawsuit in the U.S. District Court for the District of New Jersey alleging that temporary restraining order to halt Lilly’s advertisements for Zepbound and Mounjaro compare the highest approved doses of its products with lower‑dose versions advertising that it says misrepresents weight‑loss outcomes. Analysts have begun coverage of Novo’s Wegovy and Ozempic while ignoring Novo’s newly approved 7.2 mg Wegovy dose. Novo seeks Nordisk with a permanent injunction, corrective advertising BUY rating and damages, arguing a $68 price target, citing the campaigns mislead consumers about relative efficacy. Observational studies in North America and Europe link semaglutide expanding obesity market, the oral Wegovy launch, and other GLP‑1 agonists to lower rates of obesity‑related cancers, a 30 % reduction in breast‑cancer incidence pipeline that includes higher‑dose Wegovy, CagriSema and a 40‑70 % decrease in first‑time Alzheimer diagnoses. Zenagamtide, while noting competition, pricing pressure and an upcoming patent cliff.

Versions

  1. 2026-07-27 01:35 UTC Novo Nordisk obesity portfolio: EU approval, legal fight
  2. 2026-07-25 18:17 UTC Novo Nordisk obesity portfolio expands, legal fight, access

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.